<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cloudbreak Pharma, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/cloudbreak-pharma-inc</link>
    <description>Latest news and press releases for Cloudbreak Pharma, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cloudbreak-pharma-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5d824beedb30cb6fa4719.webp</url>
      <title>Cloudbreak Pharma, Inc.</title>
      <link>https://6ix.com/company/cloudbreak-pharma-inc</link>
    </image>
    <item>
      <title>Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026</title>
      <link>https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-announces-presentation-on-its-multi-kinase-inhibition-mki-platform-and-ongoing-clinical-programs-at-eyecelerator-arvo-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-announces-presentation-on-its-multi-kinase-inhibition-mki-platform-and-ongoing-clinical-programs-at-eyecelerator-arvo-2026</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
      <description>MKIs uniquely block multiple receptor tyrosine kinases (RTKs) simultaneously, addressing the inflammatory, vascular, and fibrotic causes of serious, underserved front-of-the-eye diseases Lead MKI candidates, CBT-001 and CBT-004, demonstrated statistically significant and clinically meaningful efficacy in Phase 2 studies and have the potential to be the first FDA-approved therapies for their respective indications Topline data from the Phase 3 study of lead candidate, CBT-001 for the treatment of</description>
    </item>
    <item>
      <title>Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases</title>
      <link>https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-announces-launch-of-cloudbreakpharmacom-to-raise-awareness-of-its-pipeline-of-novel-first-in-class-therapeutics-to-treat-serious-underserved-ophthalmic-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-announces-launch-of-cloudbreakpharmacom-to-raise-awareness-of-its-pipeline-of-novel-first-in-class-therapeutics-to-treat-serious-underserved-ophthalmic-diseases</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
      <description>Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the treatment of pinguecula, is Phase 3-ready following a successful End-of-Phase-2 meeting with FDA and alignment on a path forward IRVINE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibi</description>
    </item>
    <item>
      <title>Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004</title>
      <link>https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-announces-successful-end-of-phase-2-meeting-and-alignment-with-fda-on-phase-3-path-forward-for-cbt-004</link>
      <guid isPermaLink="true">https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-announces-successful-end-of-phase-2-meeting-and-alignment-with-fda-on-phase-3-path-forward-for-cbt-004</guid>
      <pubDate>Tue, 27 Jan 2026 13:00:00 GMT</pubDate>
      <description>CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ability to modify disease progression through a novel, multi-target mechanism of action Phase 3 data from lead asset, CBT-001, as a potential treatment for pterygium anticipated in Q4 2026 IRVINE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmi</description>
    </item>
    <item>
      <title>Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula</title>
      <link>https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-inc-announces-positive-phase-2-results-for-cbt-004-in-patients-with-vascularized-pinguecula</link>
      <guid isPermaLink="true">https://6ix.com/company/cloudbreak-pharma-inc/news/cloudbreak-pharma-inc-announces-positive-phase-2-results-for-cbt-004-in-patients-with-vascularized-pinguecula</guid>
      <pubDate>Mon, 21 Jul 2025 00:30:00 GMT</pubDate>
      <description>IRVINE, Calif., July 21, 2025--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia.</description>
    </item>
  </channel>
</rss>